A total of 105 HLA-A2 positive patients enrolled in the Combi-TED study, which explores the combination of Tedopi® with either an anti-PD1 checkpoint inhibitor or chemotherapy as a second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback